Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus adjuvant endocrine therapy versus adjuvant endocrine therapy alone in high-risk HR-positive/HER2-negative early breast cancer
2016-004362-26Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abemaciclib in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Invasive disease-free survival. Started Apr 2017; status: active.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-004362-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004362-26.